FRINK Linked Data Fragments server

Matches in Wikidata for { <http://www.wikidata.org/entity/Q37065959> ?p ?o ?g. }

• Q37065959 description "2012 nî lūn-bûn" @default.
• Q37065959 description "2012年の論文" @default.
• Q37065959 description "2012年学术文章" @default.
• Q37065959 description "2012年学术文章" @default.
• Q37065959 description "2012年学术文章" @default.
• Q37065959 description "2012年学术文章" @default.
• Q37065959 description "2012年学术文章" @default.
• Q37065959 description "2012年學術文章" @default.
• Q37065959 description "2012年學術文章" @default.
• Q37065959 description "2012年學術文章" @default.
• Q37065959 description "2012年學術文章" @default.
• Q37065959 description "2012年學術文章" @default.
• Q37065959 description "2012年學術文章" @default.
• Q37065959 description "2012년 논문" @default.
• Q37065959 description "article científic" @default.
• Q37065959 description "article scientific" @default.
• Q37065959 description "article scientifique publié en 2012" @default.
• Q37065959 description "articol științific" @default.
• Q37065959 description "articolo scientifico" @default.
• Q37065959 description "artigo científico (publicado na 2012)" @default.
• Q37065959 description "artigo científico (publicado na 2012)" @default.
• Q37065959 description "artigo científico" @default.
• Q37065959 description "artikull shkencor" @default.
• Q37065959 description "artikulong pang-agham" @default.
• Q37065959 description "artykuł naukowy" @default.
• Q37065959 description "artículo científico publicado en 2012" @default.
• Q37065959 description "artículu científicu espublizáu en 2012" @default.
• Q37065959 description "bilimsel makale" @default.
• Q37065959 description "bài báo khoa học" @default.
• Q37065959 description "mokslinis straipsnis" @default.
• Q37065959 description "naučni članak" @default.
• Q37065959 description "scienca artikolo" @default.
• Q37065959 description "scientific article published on 30 July 2012" @default.
• Q37065959 description "teaduslik artikkel" @default.
• Q37065959 description "tieteellinen artikkeli" @default.
• Q37065959 description "tudományos cikk" @default.
• Q37065959 description "vedecký článok" @default.
• Q37065959 description "vetenskaplig artikel" @default.
• Q37065959 description "videnskabelig artikel (udgivet 2012)" @default.
• Q37065959 description "vitenskapelig artikkel" @default.
• Q37065959 description "vitskapeleg artikkel" @default.
• Q37065959 description "vědecký článek" @default.
• Q37065959 description "wetenschappelijk artikel" @default.
• Q37065959 description "wissenschaftlicher Artikel" @default.
• Q37065959 description "επιστημονικό άρθρο" @default.
• Q37065959 description "мақолаи илмӣ" @default.
• Q37065959 description "мақолаи илмӣ" @default.
• Q37065959 description "наукова стаття, опублікована в липні 2012" @default.
• Q37065959 description "научна статия" @default.
• Q37065959 description "научная статья" @default.
• Q37065959 description "научни чланак" @default.
• Q37065959 description "научни чланак" @default.
• Q37065959 description "գիտական հոդված" @default.
• Q37065959 description "מאמר מדעי" @default.
• Q37065959 description "سائنسی مضمون" @default.
• Q37065959 description "مقالة علمية نشرت في 30 يوليو 2012" @default.
• Q37065959 description "مقالهٔ علمی" @default.
• Q37065959 description "২০১২-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ" @default.
• Q37065959 description "บทความทางวิทยาศาสตร์" @default.
• Q37065959 description "სამეცნიერო სტატია" @default.
• Q37065959 name "Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499" @default.
• Q37065959 name "Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499" @default.
• Q37065959 name "Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499." @default.
• Q37065959 type Item @default.
• Q37065959 label "Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499" @default.
• Q37065959 label "Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499" @default.
• Q37065959 label "Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499." @default.
• Q37065959 prefLabel "Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499" @default.
• Q37065959 prefLabel "Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499" @default.
• Q37065959 prefLabel "Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499." @default.
• Q37065959 P1433 Q37065959-37939142-B5D2-4F60-8A38-62BD0609CA40 @default.
• Q37065959 P1476 Q37065959-9A0D742A-836D-4CD4-978F-A6432CA474DC @default.
• Q37065959 P2093 Q37065959-301121F6-BB21-4B64-B9AA-D37EDF1CE62F @default.
• Q37065959 P2093 Q37065959-9841B39B-BD98-46CA-A356-B2C7E7EEF535 @default.
• Q37065959 P2093 Q37065959-A4E75A70-491E-4C74-B6AD-1B42E3F3EF0E @default.
• Q37065959 P2093 Q37065959-B1E5B9A7-D2BA-4182-866D-4AF25D618628 @default.
• Q37065959 P2093 Q37065959-B27FA019-D253-4DDD-A071-E6A98B639D5E @default.
• Q37065959 P2093 Q37065959-DAC25554-5EBE-47A2-B918-49C5C1A0A716 @default.
• Q37065959 P2093 Q37065959-EBB91F6F-018A-48E1-995C-587D0E6355AA @default.
• Q37065959 P2860 Q37065959-01C6EFE4-31E4-4080-9D46-4DCFE5CA7D73 @default.
• Q37065959 P2860 Q37065959-039E80C7-7217-4D57-82F8-0CF8EE762295 @default.
• Q37065959 P2860 Q37065959-0414A4E7-E56B-4C03-974E-F6B5258304AA @default.
• Q37065959 P2860 Q37065959-0D3D4108-0F83-4E07-87EA-EAD0D8014BFC @default.
• Q37065959 P2860 Q37065959-14296B51-3DBE-4AFC-B02C-FE3A620BD955 @default.
• Q37065959 P2860 Q37065959-16A870A9-1B9F-4AF1-917F-62590EEEAA7F @default.
• Q37065959 P2860 Q37065959-1D36D3BE-EBF0-4CF5-98EE-7511F17D5F24 @default.
• Q37065959 P2860 Q37065959-239EE5F6-5C5A-4129-BDA1-157637EC8184 @default.
• Q37065959 P2860 Q37065959-32EB897F-762A-461E-AD30-14A7DAAD376E @default.
• Q37065959 P2860 Q37065959-58E7B2D4-4423-4AED-902B-F5BC2ABAD332 @default.
• Q37065959 P2860 Q37065959-5D623E14-9880-4211-AF94-C060C1BFA5F4 @default.
• Q37065959 P2860 Q37065959-5DC58183-8FC7-4D6A-AFE2-D451228FD552 @default.
• Q37065959 P2860 Q37065959-6187A539-5CA1-4E06-B298-0C51E597BB35 @default.
• Q37065959 P2860 Q37065959-7413CF09-4E1E-4432-BFC3-6F881DC69CD9 @default.
• Q37065959 P2860 Q37065959-75D8C0F7-7C3F-40CC-A3DF-9E1FCDB5DF87 @default.
• Q37065959 P2860 Q37065959-8D6500DB-C7F1-4487-9ABE-46686775555E @default.
• Q37065959 P2860 Q37065959-91F65E0A-E77A-45F7-B45C-3844C8A48AA5 @default.
• Q37065959 P2860 Q37065959-955B17D9-5948-4050-8DF7-E245A2B385A3 @default.
• Q37065959 P2860 Q37065959-9FBB7503-6FEA-4F37-A8FD-C0302CA5F78D @default.
• Q37065959 P2860 Q37065959-B31DFD0E-3780-40C8-B2B4-AC3A611BB6DD @default.
• Q37065959 P2860 Q37065959-B9C0D044-6159-485C-AF23-7430DCABDCB2 @default.

• next